Headlines about RTI Surgical (NASDAQ:RTIX) have been trending somewhat positive this week, according to Accern. The research firm identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. RTI Surgical earned a news sentiment score of 0.12 on Accern’s scale. Accern also gave headlines about the medical equipment provider an impact score of 46.6050035964805 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

A number of equities research analysts recently issued reports on RTIX shares. BidaskClub lowered RTI Surgical from a “hold” rating to a “sell” rating in a research note on Wednesday, March 28th. ValuEngine raised RTI Surgical from a “hold” rating to a “buy” rating in a research note on Monday, July 2nd. Finally, Zacks Investment Research raised RTI Surgical from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd.

RTIX stock traded down $0.20 on Wednesday, reaching $4.70. The company had a trading volume of 136,843 shares, compared to its average volume of 131,214. RTI Surgical has a 1 year low of $3.85 and a 1 year high of $5.90. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.53 and a current ratio of 3.81. The firm has a market cap of $307.62 million, a P/E ratio of 94.00, a PEG ratio of 3.23 and a beta of 1.56.

RTI Surgical (NASDAQ:RTIX) last issued its quarterly earnings results on Thursday, May 3rd. The medical equipment provider reported $0.01 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.01. RTI Surgical had a return on equity of 2.49% and a net margin of 2.57%. The company had revenue of $69.89 million for the quarter, compared to analyst estimates of $68.70 million. research analysts predict that RTI Surgical will post 0.1 earnings per share for the current year.

RTI Surgical Company Profile

RTI Surgical, Inc, together with its subsidiaries, designs, develops, manufactures, and distributes biologic, metal, and synthetic implants worldwide. It processes donated human musculoskeletal and other tissues, as well as bovine and porcine animal tissues to produce allograft and xenograft implants by using its proprietary BIOCLEANSE, TUTOPLAST, and CANCELLE SP sterilization processes.

Insider Buying and Selling by Quarter for RTI Surgical (NASDAQ:RTIX)

Receive News & Ratings for RTI Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RTI Surgical and related companies with MarketBeat.com's FREE daily email newsletter.